Nobuhiro Nishibori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nobuhiro Nishibori has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Shoichi Maruyama
Department of Nephrology Nagoya University Graduate School of Medicine Nagoya Japan
8 shared publications - Takahiro Imaizumi
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan
7 shared publications - Masaki Okazaki
Department of Nephrology, Nagoya University Graduate School of Medicine , Nagoya
6 shared publications - Shimon Kurasawa
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
6 shared publications - Hirotake Kasuga
Department of Nephrology, Nagoya Kyoritsu Hospital, Nagoya, Japan
3 shared publications - Koya Nagase
Department of Nephrology, Nagoya University Graduate School of Medicine , Nagoya
3 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Background and hypothesis: Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods: Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Results: Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. Conclusion: In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
- 2 November 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Open AccessHypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients
Background and hypothesis: Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Methods: Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Results: Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90–26.1) for denosumab and 8.09 (2.20–29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. Conclusion: In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.
- 19 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Care gaps following newly detected dipstick proteinuria in treated hypertension: a Japanese nationwide database study
Aims: Clinical guidelines recommend follow-up quantitative testing after dipstick-positive proteinuria and, when proteinuria is confirmed, subsequent initiation of renin–angiotensin system inhibitors (RASi) in patients with hypertension. However, real-world adherence to these recommendations remains unclear. We investigated management patterns following newly detected dipstick proteinuria in patients with treated hypertension. Methods and results: Using the JMDC claims database, we identified treated hypertensive patients with newly detected dipstick proteinuria (≥1+, with prior results <1+) between January 2005 and March 2025. The study outcomes were quantitative urine albumin/protein testing and RASi initiation. Cumulative incidence was estimated using the Kaplan–Meier method, and multivariable Cox models were used to identify factors associated with outcomes. The 365-day cumulative incidence of quantitative testing was 7.5% [95% confidence interval (CI): 7.2–7.7] in the overall population (n = 47 210), and that of RASi initiation was 13.2% (95% CI: 12.6–13.8) among baseline RASi non-users (n = 14 599). Both outcomes became more frequent with increasing dipstick grade but remained infrequent in the higher-grade groups: among patients with 2+ and 3+ proteinuria, quantitative testing was performed in 12.9 and 16.1%, respectively, and RASi initiation occurred in 17.5 and 21.7%, respectively. Temporal trend analysis indicated that RASi initiation rates showed no improvement (adjusted hazard ratio [aHR] per year: 1.01; 95% CI: 0.99–1.03). Conclusion: Follow-up quantitative testing and RASi initiation after newly detected dipstick proteinuria were infrequent, even among patients with higher dipstick grades, and RASi initiation showed no clear improvement over time. These findings highlight opportunities to improve guideline-concordant urinary protein assessment and antihypertensive therapy.
- 19 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Care gaps following newly detected dipstick proteinuria in treated hypertension: a Japanese nationwide database study
Aims: Clinical guidelines recommend follow-up quantitative testing after dipstick-positive proteinuria and, when proteinuria is confirmed, subsequent initiation of renin–angiotensin system inhibitors (RASi) in patients with hypertension. However, real-world adherence to these recommendations remains unclear. We investigated management patterns following newly detected dipstick proteinuria in patients with treated hypertension. Methods and results: Using the JMDC claims database, we identified treated hypertensive patients with newly detected dipstick proteinuria (≥1+, with prior results <1+) between January 2005 and March 2025. The study outcomes were quantitative urine albumin/protein testing and RASi initiation. Cumulative incidence was estimated using the Kaplan–Meier method, and multivariable Cox models were used to identify factors associated with outcomes. The 365-day cumulative incidence of quantitative testing was 7.5% [95% confidence interval (CI): 7.2–7.7] in the overall population (n = 47 210), and that of RASi initiation was 13.2% (95% CI: 12.6–13.8) among baseline RASi non-users (n = 14 599). Both outcomes became more frequent with increasing dipstick grade but remained infrequent in the higher-grade groups: among patients with 2+ and 3+ proteinuria, quantitative testing was performed in 12.9 and 16.1%, respectively, and RASi initiation occurred in 17.5 and 21.7%, respectively. Temporal trend analysis indicated that RASi initiation rates showed no improvement (adjusted hazard ratio [aHR] per year: 1.01; 95% CI: 0.99–1.03). Conclusion: Follow-up quantitative testing and RASi initiation after newly detected dipstick proteinuria were infrequent, even among patients with higher dipstick grades, and RASi initiation showed no clear improvement over time. These findings highlight opportunities to improve guideline-concordant urinary protein assessment and antihypertensive therapy.
- Open Access
- 30 June 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (8)
Key predictors of mortality in profound hyponatremia beyond the correction rate
Background: Current guidelines for hyponatremia recommend slow sodium correction; however, recent large-scale observational studies have associated slow correction with increased mortality. The association between correction rate and mortality can be influenced by numerous factors, including comorbidities, overall condition, and treatment interventions, but this complex interplay remains unclear. We aimed to clarify this association by developing interpretable machine learning models using detailed clinical features. Methods: We included 546 patients with serum sodium ≤120 mEq/L, collected clinical features through chart review, and developed four machine learning models to predict in-hospital mortality. The best-performing model, selected by the area under the receiver operating characteristic curve (ROC-AUC), was interpreted using SHapley Additive exPlanations (SHAP) to quantify each feature’s contribution to mortality prediction. Results: In-hospital mortality was 18%. The random forest model demonstrated the best predictive performance (ROC-AUC = 0.907; 95% CI, 0.832–0.965). SHAP analysis revealed that the most influential predictors were baseline characteristics reflecting underlying illness severity: serum albumin, C-reactive protein, Charlson Comorbidity Index, and metastatic malignancy; their predictive effects were consistent across correction rates. Among treatment-related features, intravenous fluid choice and sodium monitoring frequency had a greater predictive impact than correction rate. Although slower correction was associated with higher mortality, the correction rate ranked 14th among all 59 features in predictive importance. Conclusions: In profound hyponatremia, multiple key predictors of mortality exist beyond the correction rate. These findings suggest that the observed association between slow correction and higher mortality may not be causal but rather an epiphenomenon driven by underlying illness severity and treatment intensity.
- 30 June 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (8)
Open AccessKey predictors of mortality in profound hyponatremia beyond the correction rate
Background: Current guidelines for hyponatremia recommend slow sodium correction; however, recent large-scale observational studies have associated slow correction with increased mortality. The association between correction rate and mortality can be influenced by numerous factors, including comorbidities, overall condition, and treatment interventions, but this complex interplay remains unclear. We aimed to clarify this association by developing interpretable machine learning models using detailed clinical features. Methods: We included 546 patients with serum sodium ≤120 mEq/L, collected clinical features through chart review, and developed four machine learning models to predict in-hospital mortality. The best-performing model, selected by the area under the receiver operating characteristic curve (ROC-AUC), was interpreted using SHapley Additive exPlanations (SHAP) to quantify each feature’s contribution to mortality prediction. Results: In-hospital mortality was 18%. The random forest model demonstrated the best predictive performance (ROC-AUC = 0.907; 95% CI, 0.832–0.965). SHAP analysis revealed that the most influential predictors were baseline characteristics reflecting underlying illness severity: serum albumin, C-reactive protein, Charlson Comorbidity Index, and metastatic malignancy; their predictive effects were consistent across correction rates. Among treatment-related features, intravenous fluid choice and sodium monitoring frequency had a greater predictive impact than correction rate. Although slower correction was associated with higher mortality, the correction rate ranked 14th among all 59 features in predictive importance. Conclusions: In profound hyponatremia, multiple key predictors of mortality exist beyond the correction rate. These findings suggest that the observed association between slow correction and higher mortality may not be causal but rather an epiphenomenon driven by underlying illness severity and treatment intensity.
- Open Access
- 29 October 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (3) , 602-612
Impact of Left Ventricular Geometry on All-Cause Mortality in Patients Undergoing Hemodialysis
Key Points: We evaluated the association between the four categories of left ventricular geometry and all-cause mortality in patients undergoing hemodialysis. Concentric hypertrophy was the most prevalent, followed by concentric remodeling, and these were associated with a high risk of mortality. Echocardiography screening for evaluating the four categories of left ventricular geometry may be useful for risk prediction in patients undergoing hemodialysis. Background: Left ventricular (LV) geometry, which is classified into four categories on the basis of left ventricular mass index and relative wall thickness, can predict mortality more accurately than the presence of LV hypertrophy alone in patients with hypertension. However, this association remains inconclusive in patients undergoing maintenance hemodialysis. Methods: We conducted a retrospective multicenter cohort study involving patients undergoing maintenance hemodialysis in Japan who underwent echocardiography between October 2006 and December 2021. The exposure of interest was LV geometry abnormalities (concentric remodeling, eccentric hypertrophy, and concentric hypertrophy). The primary outcome of this study was all-cause death. Results: Among the 2228 patients included in the analysis (mean age, 67 years; 67% male individuals; median dialysis vintage, 1.5 years), 476 (21%) had normal geometry, 592 (27%) had concentric remodeling, 493 (22%) had eccentric hypertrophy, and 667 (30%) had concentric hypertrophy. During a median follow-up period of 3.8 years, 825 patients (37%) died. Compared with patients with normal geometry, those with concentric hypertrophy (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.06 to 1.63) and concentric remodeling (aHR, 1.27; 95% CI, 1.02 to 1.58) had a higher risk of mortality. Eccentric hypertrophy was associated with a similar risk of mortality (aHR, 1.03; 95% CI, 0.81 to 1.30) compared with normal geometry. Conclusions: Approximately 80% of patients undergoing maintenance hemodialysis exhibited abnormal LV geometry, with concentric hypertrophy being the most common pattern, followed by concentric remodeling. These abnormalities were associated with a higher risk of all-cause mortality compared with normal geometry. Risk prediction on the basis of the presence or absence of LV hypertrophy cannot consider concentric remodeling; therefore, echocardiography screening for evaluating the four categories of LV geometry may be beneficial in patients undergoing hemodialysis.
- 29 October 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (3) , 602-612
Open AccessImpact of Left Ventricular Geometry on All-Cause Mortality in Patients Undergoing Hemodialysis
Key Points: We evaluated the association between the four categories of left ventricular geometry and all-cause mortality in patients undergoing hemodialysis. Concentric hypertrophy was the most prevalent, followed by concentric remodeling, and these were associated with a high risk of mortality. Echocardiography screening for evaluating the four categories of left ventricular geometry may be useful for risk prediction in patients undergoing hemodialysis. Background: Left ventricular (LV) geometry, which is classified into four categories on the basis of left ventricular mass index and relative wall thickness, can predict mortality more accurately than the presence of LV hypertrophy alone in patients with hypertension. However, this association remains inconclusive in patients undergoing maintenance hemodialysis. Methods: We conducted a retrospective multicenter cohort study involving patients undergoing maintenance hemodialysis in Japan who underwent echocardiography between October 2006 and December 2021. The exposure of interest was LV geometry abnormalities (concentric remodeling, eccentric hypertrophy, and concentric hypertrophy). The primary outcome of this study was all-cause death. Results: Among the 2228 patients included in the analysis (mean age, 67 years; 67% male individuals; median dialysis vintage, 1.5 years), 476 (21%) had normal geometry, 592 (27%) had concentric remodeling, 493 (22%) had eccentric hypertrophy, and 667 (30%) had concentric hypertrophy. During a median follow-up period of 3.8 years, 825 patients (37%) died. Compared with patients with normal geometry, those with concentric hypertrophy (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.06 to 1.63) and concentric remodeling (aHR, 1.27; 95% CI, 1.02 to 1.58) had a higher risk of mortality. Eccentric hypertrophy was associated with a similar risk of mortality (aHR, 1.03; 95% CI, 0.81 to 1.30) compared with normal geometry. Conclusions: Approximately 80% of patients undergoing maintenance hemodialysis exhibited abnormal LV geometry, with concentric hypertrophy being the most common pattern, followed by concentric remodeling. These abnormalities were associated with a higher risk of all-cause mortality compared with normal geometry. Risk prediction on the basis of the presence or absence of LV hypertrophy cannot consider concentric remodeling; therefore, echocardiography screening for evaluating the four categories of LV geometry may be beneficial in patients undergoing hemodialysis.
- Open Access
- 9 December 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (3) , 420-431
Plasma Metabolite Profiles Between In-Center Daytime Extended-Hours and Conventional Hemodialysis
Key Points: Significant differences in 39 plasma metabolites were observed between patients on extended-hours hemodialysis and those on conventional hemodialysis. Extended-hours hemodialysis had a lower lactate-to-pyruvate ratio and higher branched-chain amino acids than conventional hemodialysis. Extended-hours hemodialysis may have favorable metabolic and nutritional benefits for patients undergoing maintenance hemodialysis. Background: Protein–energy wasting, characterized by disordered body protein catabolism resulting from metabolic and nutritional derangements, is associated with adverse clinical outcomes in patients undergoing hemodialysis. Extended-hours hemodialysis (≥6 hours per treatment session) offers both enhanced removal of uremic solutes and better fluid management, generally allowing more liberalized dietary protein and calorie intake. The aim of this study was to evaluate the difference in plasma metabolite profiles among patients receiving in-center daytime extended-hours hemodialysis and those receiving conventional hemodialysis. Methods: Predialysis plasma samples were obtained from 188 patients on extended-hours hemodialysis (21.9 h/wk) and 286 patients on conventional hemodialysis (12.1 h/wk) in Japan in 2020 using capillary electrophoresis-mass spectrometry. Group differences were compared for 117 metabolites using Wilcoxon rank-sum tests with multiple comparisons and partial least squares discriminant analysis. In addition, propensity score–adjusted multiple regression analyses were performed to evaluate group differences for known uremic toxins, branched-chain amino acids, and lactate-to-pyruvate ratio (a possible surrogate marker of mitochondrial dysfunction). Results: Significant differences were observed in 39 metabolites, largely consistent with the high variable importance for prediction in partial least squares discriminant analysis. Among known uremic toxins, uridine and hypoxanthine levels were significantly higher in the conventional hemodialysis group than in the extended-hours hemodialysis group, whereas trimethylamine N-oxide levels were higher in the extended-hours hemodialysis group than in the conventional hemodialysis group. Patients on extended-hours hemodialysis had higher levels of all branched-chain amino acids and a lower lactate-to-pyruvate ratio than those on conventional hemodialysis (significant difference of −8.6 [95% confidence interval, −9.8 to −7.4]). Conclusions: Extended-hours hemodialysis was associated with a more favorable plasma metabolic and amino acid profile; however, concentrations of most uremic toxins did not significantly differ from those of conventional hemodialysis.
- 9 December 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (3) , 420-431
Open AccessPlasma Metabolite Profiles Between In-Center Daytime Extended-Hours and Conventional Hemodialysis
Key Points: Significant differences in 39 plasma metabolites were observed between patients on extended-hours hemodialysis and those on conventional hemodialysis. Extended-hours hemodialysis had a lower lactate-to-pyruvate ratio and higher branched-chain amino acids than conventional hemodialysis. Extended-hours hemodialysis may have favorable metabolic and nutritional benefits for patients undergoing maintenance hemodialysis. Background: Protein–energy wasting, characterized by disordered body protein catabolism resulting from metabolic and nutritional derangements, is associated with adverse clinical outcomes in patients undergoing hemodialysis. Extended-hours hemodialysis (≥6 hours per treatment session) offers both enhanced removal of uremic solutes and better fluid management, generally allowing more liberalized dietary protein and calorie intake. The aim of this study was to evaluate the difference in plasma metabolite profiles among patients receiving in-center daytime extended-hours hemodialysis and those receiving conventional hemodialysis. Methods: Predialysis plasma samples were obtained from 188 patients on extended-hours hemodialysis (21.9 h/wk) and 286 patients on conventional hemodialysis (12.1 h/wk) in Japan in 2020 using capillary electrophoresis-mass spectrometry. Group differences were compared for 117 metabolites using Wilcoxon rank-sum tests with multiple comparisons and partial least squares discriminant analysis. In addition, propensity score–adjusted multiple regression analyses were performed to evaluate group differences for known uremic toxins, branched-chain amino acids, and lactate-to-pyruvate ratio (a possible surrogate marker of mitochondrial dysfunction). Results: Significant differences were observed in 39 metabolites, largely consistent with the high variable importance for prediction in partial least squares discriminant analysis. Among known uremic toxins, uridine and hypoxanthine levels were significantly higher in the conventional hemodialysis group than in the extended-hours hemodialysis group, whereas trimethylamine N-oxide levels were higher in the extended-hours hemodialysis group than in the conventional hemodialysis group. Patients on extended-hours hemodialysis had higher levels of all branched-chain amino acids and a lower lactate-to-pyruvate ratio than those on conventional hemodialysis (significant difference of −8.6 [95% confidence interval, −9.8 to −7.4]). Conclusions: Extended-hours hemodialysis was associated with a more favorable plasma metabolic and amino acid profile; however, concentrations of most uremic toxins did not significantly differ from those of conventional hemodialysis.
- Open Access
- 6 May 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (6) , sfae121
Association of calciprotein particles with serum phosphorus among patients undergoing conventional and extended-hours haemodialysis
Extended-hours haemodialysis (HD) is associated with better clinical outcomes than conventional HD. We investigated whether extended-hours HD and conventional HD have varying effects on blood levels of calciprotein particles (CPP) and phosphorus, which have been identified as major pathogenic molecules for vascular calcification. Patients who underwent conventional or extended in-centre daytime HD between January and March 2020 were included. Plasma CPP levels, representing only secondary CPP (CPP-Ⅱ), were measured in pre-dialysis samples. Linear and non-linear associations between CPP and serum phosphorus levels were examined across dialysis modalities. A total of 382 participants (185 undergoing extended-hours HD and 197 undergoing conventional HD) were included in the analysis. The median age of participants was 71 years, 65% of the patients were men, and the mean phosphorus level was 5.4 mg/dL. Plasma CPP (CPP-Ⅱ) levels were lower in the extended-hours HD group than in the conventional HD group (40 018 AU vs. 75 728 AU, p < 0.01). Multivariable linear regression analysis showed that extended-hours HD was associated with lower natural logarithmic plasma CPP (CPP-Ⅱ) levels: -0.64 (95% CI: -0.74 to -0.55). Restricted cubic spline function indicated that extended-hours HD was associated with lower plasma CPP (CPP-Ⅱ) levels across levels of serum phosphorus, with significant differences observed between groups, especially in hyperphosphatemic conditions (P for interaction < 0.01). The extended-hours HD group had lower CPP levels than the conventional HD group despite no significant differences in serum phosphorus levels, which may contribute to better clinical outcomes in patients on extended-hours HD.
- 6 May 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (6) , sfae121
Open AccessAssociation of calciprotein particles with serum phosphorus among patients undergoing conventional and extended-hours haemodialysis
Extended-hours haemodialysis (HD) is associated with better clinical outcomes than conventional HD. We investigated whether extended-hours HD and conventional HD have varying effects on blood levels of calciprotein particles (CPP) and phosphorus, which have been identified as major pathogenic molecules for vascular calcification. Patients who underwent conventional or extended in-centre daytime HD between January and March 2020 were included. Plasma CPP levels, representing only secondary CPP (CPP-Ⅱ), were measured in pre-dialysis samples. Linear and non-linear associations between CPP and serum phosphorus levels were examined across dialysis modalities. A total of 382 participants (185 undergoing extended-hours HD and 197 undergoing conventional HD) were included in the analysis. The median age of participants was 71 years, 65% of the patients were men, and the mean phosphorus level was 5.4 mg/dL. Plasma CPP (CPP-Ⅱ) levels were lower in the extended-hours HD group than in the conventional HD group (40 018 AU vs. 75 728 AU, p < 0.01). Multivariable linear regression analysis showed that extended-hours HD was associated with lower natural logarithmic plasma CPP (CPP-Ⅱ) levels: -0.64 (95% CI: -0.74 to -0.55). Restricted cubic spline function indicated that extended-hours HD was associated with lower plasma CPP (CPP-Ⅱ) levels across levels of serum phosphorus, with significant differences observed between groups, especially in hyperphosphatemic conditions (P for interaction < 0.01). The extended-hours HD group had lower CPP levels than the conventional HD group despite no significant differences in serum phosphorus levels, which may contribute to better clinical outcomes in patients on extended-hours HD.
- Open Access
- 24 February 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 24 (7) , 909-920
Number of calcified aortic valve leaflets: natural history and prognostic value in patients undergoing haemodialysis
Aims: Aortic valve calcification in aortic sclerosis, a precursor of aortic stenosis (AS), is not always present in all three leaflets; how calcification develops in each leaflet is unknown. We aimed to investigate the natural history of calcification development in each aortic valve leaflet and the prognostic value of the number of calcified leaflets. Methods and results: In a retrospective multicentre cohort study of patients undergoing haemodialysis without AS, we observed calcification development in each aortic valve leaflet using echocardiography. We investigated the association between the number of calcified leaflets and AS development and mortality using time-to-event analysis. Among the 1507 patients (mean age, 66 years; 66% male) included in the longitudinal echocardiography analysis, 709 (47%) had aortic sclerosis at baseline: one-leaflet calcified, 370 (52%); two-leaflet calcified, 215 (30%); and three-leaflet calcified, 124 (17%). The median time for one calcified leaflet increase was 3–4 years, and 251 (17%) patients developed AS during a median 3.2-year follow-up. The increased number of calcified aortic valve leaflets was associated with developing AS; compared with that of one-leaflet calcified, the adjusted hazard ratios (aHRs) [95% confidence intervals (CIs)] of two- and three-leaflet calcified were 2.12 (1.49–3.00) and 4.43 (3.01–6.52), respectively; the aHR (95% CI) per one calcified leaflet increase was 2.24 (1.96–2.55). It was also associated with all-cause mortality; the aHR (95% CI) per one calcified leaflet increase was 1.18 (1.08–1.27). Conclusion: The number of calcified aortic valve leaflets strongly predicted AS development and even mortality in patients undergoing haemodialysis, suggesting the usefulness of assessing calcification for each valve leaflet separately using echocardiography.
- 24 February 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 24 (7) , 909-920
Open AccessNumber of calcified aortic valve leaflets: natural history and prognostic value in patients undergoing haemodialysis
Aims: Aortic valve calcification in aortic sclerosis, a precursor of aortic stenosis (AS), is not always present in all three leaflets; how calcification develops in each leaflet is unknown. We aimed to investigate the natural history of calcification development in each aortic valve leaflet and the prognostic value of the number of calcified leaflets. Methods and results: In a retrospective multicentre cohort study of patients undergoing haemodialysis without AS, we observed calcification development in each aortic valve leaflet using echocardiography. We investigated the association between the number of calcified leaflets and AS development and mortality using time-to-event analysis. Among the 1507 patients (mean age, 66 years; 66% male) included in the longitudinal echocardiography analysis, 709 (47%) had aortic sclerosis at baseline: one-leaflet calcified, 370 (52%); two-leaflet calcified, 215 (30%); and three-leaflet calcified, 124 (17%). The median time for one calcified leaflet increase was 3–4 years, and 251 (17%) patients developed AS during a median 3.2-year follow-up. The increased number of calcified aortic valve leaflets was associated with developing AS; compared with that of one-leaflet calcified, the adjusted hazard ratios (aHRs) [95% confidence intervals (CIs)] of two- and three-leaflet calcified were 2.12 (1.49–3.00) and 4.43 (3.01–6.52), respectively; the aHR (95% CI) per one calcified leaflet increase was 2.24 (1.96–2.55). It was also associated with all-cause mortality; the aHR (95% CI) per one calcified leaflet increase was 1.18 (1.08–1.27). Conclusion: The number of calcified aortic valve leaflets strongly predicted AS development and even mortality in patients undergoing haemodialysis, suggesting the usefulness of assessing calcification for each valve leaflet separately using echocardiography.